TY - JOUR T1 - Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 JF - Journal for ImmunoTherapy of Cancer JO - J Immunother Cancer DO - 10.1136/jitc-2021-004272 VL - 10 IS - 1 SP - e004272 AU - Alexander Eggermont AU - Michal Kicinski AU - Stefan Suciu Y1 - 2022/01/01 UR - http://jitc.bmj.com/content/10/1/e004272.abstract ER -